Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Jul 14, 2005 10:03pm
426 Views
Post# 9281722

RE: Chief

RE: ChiefThanks for the TA lesson Chief. i have to admit, its pretty hard to overlook the knowledge of the fundamentals of the stock & management here. i still see some similarities to last year at this time when it cratered after it had pierced $5 US last Jul 12 - it had been trading in the mid $5s since May/04, but after closing at $5.46US Jul 9, it hit a low of $3.42US on Jul 13 (just two trading days later) on much higher than average volume (over 1M shares on nasdaq alone on Jul 12/13) - that penetration of a key support level seems to have brought out a lot of technical sellers since there wasn't any news (like usual) and i sense the same thing could happen if this thing ever cracked $3US decisively. it may not stay at $2.10 or $2.15 very long, but that would only be a 30% drop from these levels, as opposed to the almost 40% drop last july. perhaps the rally in biotechs will prevent this scenario, or friendly buyers will step in to prevent it from tanking again. would amaranth go short onc when the biotechs are rallying, perhaps to set up a financing at "higher" prices to help onc pay for all those manufacturing expenses? thats where i have a real problem ignoring the fundamentals. all jmho of course.
Bullboard Posts